|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.95 USD | +17.66% |
|
-34.03% | -96.50% |
| Apr. 19 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
| Apr. 19 | Top Premarket Decliners | MT |
Sunshine Biopharma, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 4.35 million compared to USD 0.228426 million a year ago. Net loss was USD 26.74 million compared to USD 12.44 million a year ago.
Basic loss per share from continuing operations was USD 1.76 compared to USD 4.76 a year ago. Diluted loss per share from continuing operations was USD 1.76 compared to USD 4.76 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -96.50% | 945K | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
SUNSHINE BIOPHARMA, INC. 
